Biotech Values

[DewDiligence]

OCUL phase-3 miss for glaucoma insert relative to placebo:

https://www.businesswire.com/news/home/20190520005742/en

The trial’s primary efficacy endpoint was to demonstrate a statistically superior mean reduction of IOP from baseline for OTX-TP treated subjects compared with placebo insert treated subjects at nine different time points, three diurnal time points (8 AM, 10 AM, and 4 PM) at each of 2, 6, and 12 weeks following insertion. Topline results show that the trial did not achieve its primary endpoint of statistically significant superiority in mean reduction of IOP compared with placebo at all nine time points.

The stock appears to be halted.